Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IIOngoingApr 17, 2019LOSARTAN POTASSIUM TABLETSCGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.Torrent Pharma Inc. · D-1115-2019Class IIOngoingApr 17, 2019LOSARTAN POTASSIUM TABLETSCGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level.Torrent Pharma Inc. · D-1114-2019Class IITerminatedApr 17, 2019Gavilyte-NLabeling Not Elsewhere Classified; orange and cherry flavor packets incorrect list "natural lemon flavor" as an ingredientLupin Somerset · D-1113-2019Class IITerminatedApr 17, 2019Life-Line tm Catalytic Activated Energy WaterUnapproved new drugMcDaniel Life-Line LLC · D-1112-2019Class IITerminatedApr 17, 2019Indian Herb PasteUnapproved new drugMcDaniel Life-Line LLC · D-1111-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 17.44-0.64MG-5.8MCG/ML* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1110-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 17.44-0.58MG-5.8MCG/ML* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1109-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 15-0.25MG-6MCG/ML INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1108-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 30-1 MG-20 MCG/ML* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1107-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 9-1 MG-10 MCG/ML* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1106-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 22.5-0.8MG-8.3MCG/ML INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1105-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 17.64-0.58MG-5.88MCG/ML* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1104-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 16.6-0.55 MG-11.1 MCG/ML* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1103-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 15-0.5MG-10MCG/ML INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1102-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 30-2 MG-30 MCG/ML* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1101-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE 30-0.5 MG/ML INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1100-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE 15-0.5MGMG/ML INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1099-2019Class IITerminatedApr 17, 2019PGE1-LIDOCAINE 40 MCG-1% /ML* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1098-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 30-1.6 MG-16 MCG/ML* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1097-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 23-0.96MG-19.2MCG/ML INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1096-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 17.16-0.57MG-19.45MCG/ML* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1095-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 12-1MG-10MCG/ML INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1094-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 30-1 MG-10 MCG/ML* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1093-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE 30-1 MG/ML* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1092-2019Class IITerminatedApr 17, 2019PGE1 40 MCG/ML* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1091-2019Class IITerminatedApr 17, 2019PAPAVERINE-PHENTOLAMINE-PGE1 22-0.8 MG-8 MCG/ML* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1090-2019Class IITerminatedApr 17, 2019HYDROXYPROGESTERONE CAPROATE 250 MG/ML OIL* INJECTABLELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1089-2019Class IITerminatedApr 17, 2019ACETYL-L-CYSTEINE 10% P.F. OPHTH SOLUTIONLack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1088-2019Class IITerminatedApr 17, 2019DEXAMETHASONELack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1087-2019Class IITerminatedApr 17, 2019SODIUM CHLORIDE PRES-FREE 5% OPHTH STERILE* SOLUTION. 20ml eye dropsLack of Processing Controls: Insanitary conditions observed during compounding of sterile drugs during recent FDA Inspection.Health Solutions Pharmacy Center Inc dba Professional Compounding Pharmacy · D-1086-2019Class IIITerminatedApr 17, 2019Clonidine HCL InjectionLabeling: Label Error on Declared Strength: Side carton panel incorrectly lists the concentration as "500 mcg Clonidine Hydrochloride" rather than the correct...X-Gen Pharmaceuticals Inc. · D-1084-2019Class IITerminatedApr 17, 2019Losartan Potassium 100 mg Tablets # 30 Losartan potassium tablets USPCGMP Deviations:Traces amounts of N-Nitroso N-Methyl 4- amino butyric acid (NMBA) impurity found in Active Pharmaceutical Ingredient (API).H J Harkins Company Inc dba Pharma Pac · D-1083-2019Class IIITerminatedApr 17, 2019Biotin 10 mg/mL InjectionFailed pH Specification: product does not meet pH label claim.Auro Pharmacies Inc. DBA Central Drugs · D-1082-2019Class IITerminatedApr 17, 2019Losartan 50mg TabletCGMP Deviations; Detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) - N-Methylnitrosobutyric acid (NMBA).RemedyRepack Inc. · D-1081-2019Class IIITerminatedApr 10, 2019Nystatin Oral SuspensionFailed Impurities/Degradation Specifications: Out of Specification for an unknown impurity was observed during the 18 month stability testing.Akorn, Inc. · D-1080-2019Class IITerminatedApr 10, 2019NORepinephrine 4 mg added to 5% Dextrose 250 mL BagLabeling: Label mix-upKRS Global Biotechnology, Inc · D-1079-2019Class IITerminatedApr 10, 2019NORepinephrine 16 mg added to 0.9% Sodium ChlorideLabeling: Label mix-upKRS Global Biotechnology, Inc · D-1078-2019Class IITerminatedApr 10, 2019Morphine Sulfate USP MilledMicrobial Contamination of Non-Sterile Products: Bioburden out of specification results for Morphine Sulfate API.Johnson Matthey Inc. · D-1077-2019Class IITerminatedApr 10, 2019Cefuroxime 10mg/mL INJ 0.5 mgPresence of Particulate Matter: Particulate matter was reported in one lot of Cefuroxime by a physician after use of product.. FDA analysis identified the particulate as...Pacific Compounding Pharmacy & Consultations Inc · D-1076-2019Class IITerminatedApr 10, 2019Losartan Potassium TabletsCGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detected.Legacy Pharmaceutical Packaging LLC · D-1075-2019